Profile: Trinity Biotech PLC (TRIB.O)
29 Aug 2014
Trinity Biotech plc (Trinity Biotech), incorporated in 1992, develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The Company is a provider of raw materials to the life sciences industry and research institutes globally through the Company subsidiary, Fitzgerald Industries. Trinity Biotech markets its portfolio of over 275 products to customers in 75 countries around the world. Trinity Biotech markets its products in the United States through a direct sales force and in the rest of the world through a combination of direct selling and a network of distributors. Trinity Biotech has manufacturing facilities in Bray, Ireland, in Jamestown, New York, Carlsbad, California and Kansas City, Missouri in the United States. On July 26, 2013, it acquired Immco Diagnostics Inc.
Point of Care (POC)
Point of Care refers to diagnostic tests which are carried out in the presence of the patient. The Company’s principal product is UniGold human immunodeficiency virus (HIV). In Africa, UniGold HIV has been used for several years in voluntary counseling and testing centres in the sub-Saharan region where they provide a cornerstone to early detection and treatment intervention. UniGold HIV is used in public health facilities, hospitals and other outreach facilities in the United States.
Trinity Biotech supplies the clinical laboratory segment of the in-vitro diagnostic market with a range of diagnostic tests and instrumentation which detect infectious diseases: bacterial and viral diseases and autoimmune disorders; HbA1c and Hb Variant: Diabetes and Haemoglobin disorders and clinical chemistry: liver & kidney disease and haemolytic anaemia. Trinity Biotech manufactures products for niche/specialized applications in Infectious Disease and Autoimmune disorders. The products are used with patient samples and the results generated help physicians to guide diagnosis for a broad range of infectious diseases. The key niche/specialist disease areas served by the Trinity Biotech products include lyme disease, sexually transmitted diseases: syphilis, chlamydia and herpes simplex, respiratory infections: legionella, flu A&B, epstein barr virus, other viral pathogens, such as measles, mumps, rubella and varicella, and autoimmune disorders.
The Company focuses on products for the in-vitro diagnostic testing for haemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes and Hb Variants for the detection of Hemoglobinapothies. It manufactures a range of instrumentation using patented high pressure liquid chromatography (HPLC) technology. The Trinity Biotech speciality clinical chemistry business includes reagent products, such as ACE, Bile Acids, Lactate, Oxalate and Glucose-6-Phosphate Dehydrogenase (G6PDH) that are clearly differentiated in the marketplace. These products are suitable for both manual and automated testing and have proven performance in the diagnosis of many disease states from liver and kidney disease to G6PDH deficiency which is an indicator of haemolytic anaemia. The Premier Hb9210 was launched in Europe during the year ended December 31, 2011.
The Company competes with Abbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Johnson & Johnson, OraSure Technologies Inc., Roche Diagnostics, Siemens, Thermo Fisher and Tosoh.
Trinity Biotech PLC
IDA Business Park, Co Wicklow